The role of PARP-2 in inhibiting prostate cancer
Published: 27 Jul 2020
Views: 448
Prof Li Jia - Harvard Medical School, Boston, USA
Prof Li Jia speaks to ecancer about the use of PARP inhibitors in treating prostate cancer.
He talks about the paper he worked on which found that the selective targeting of PARP-2 inhibits androgen receptor signalling and prostate cancer growth. He goes on to discuss the potential of selectively targeting PARP-2 in prostate cancer, particularly in castration-resistant prostate cancer.
Prof Jia explains the differences between PARP-1 and PARP-2, how they are being studied and how that research might be used in the future.
This programme has been supported by an unrestricted educational grant from Pfizer.
Related Videos
Ferroptosis regulator as a novel therapeutic target for STK11/KEAP1 co-mutant lu...
Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York, USA
20 Jan 2021
The biology and therapeutic options for STK11/KEAP1 co-mutant lung adenocarcinom...
Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York, USA
20 Jan 2021
PARP inhibitors for prostate cancer: What oncology PAs should know
Colleen Tetzlaf, PA-C, Fox Chase Cancer Center, Philadelphia, USA
18 Dec 2020
ESMO 2020: New developments in the treatment of lung cancer
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
17 Dec 2020
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...
15 Dec 2020
PARP inhibitors in prostate cancer: A promise delivered
Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA
1 Dec 2020
Association of BRCA alterations with response to PARP inhibitors in metastatic c...
Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center...
30 May 2020
ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and no...
Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob
14 Feb 2020
Targeting agent enfortumab vedotin a novel treatment for patients with advanced ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
3 Jun 2019
